Back in 2010 when Regenicin announced the deal wit
Post# of 30028
Posted On: 07/08/2015 10:02:01 PM
Back in 2010 when Regenicin announced the deal with Lonza the stock popped to $2.20 and a market cap of $185K. That was at the time Dr. Joseph Rubinfeld joined the Board of Directors. After that, the company ran into all sorts of issues.
Fast forward 5 years. What's the product now worth with the litigation cleared up and all that has transpired since that date: DoD backing, ODD, IND, Phase 2 trial starting?
Pharma-economics (Savings) for burns >50% only:
Low End: (500 Patients) X ($10K Savings/day) X (60 days) = $300M
High End: (3500 Patients) X ($15K Savings/day) X (120 days) = $6.3B
June 19, 2015 - 2015 Impact Investor Conference
18:05 - "The most important thing about this asset is it as a wealth of human efficacy data that has been out there and the key opinion leading physicians love this technology. We're talking about 3 out former past presidents of the American Burn Association are going to be involved in this 10 patient phase 2 clinical study and we think there may be some means we can get an accelerated pathway from a market perspective."
20:00 - " Near term commercial opportunity . There is no competition in terms of technology that have both layers of own skin. This is the ownly technology out there. We think in the US it's a $500M market opportunity not to mention other things diabetic foot ulcers, burns that are less than 50%, 30%, as well as ultimately some kind of cosmetic opportunity..."
June 16, 2015 - BIO International Convention at 2:30 pm ET
15:00 - "We believe this program will significantly mitigate enterprise risk as well as expose us to tremendous upside because of the data that has been produced since the physician sponsored study that is publicly available ."
11/19/2014 - AMBS: ASTUTE DEAL BRINGS IN ANOTHER SHOT ON GOAL FOR AMARANTUS BIO
11/18/2014 - Amarantus Business Update Conference Call "And with ESS-W, we feel as though we have found just a tremendous opportunity."
4/10/2014 - Development of the Mechanical Properties of Engineered Skin Substitutes After Grafting to Full-Thickness Wounds
11/23/2010 - DoD awards Regenicin and Lonza $18 million to develop PermaDerm for severe burns
8/18/2010 - Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville
Fast forward 5 years. What's the product now worth with the litigation cleared up and all that has transpired since that date: DoD backing, ODD, IND, Phase 2 trial starting?
Pharma-economics (Savings) for burns >50% only:
Low End: (500 Patients) X ($10K Savings/day) X (60 days) = $300M
High End: (3500 Patients) X ($15K Savings/day) X (120 days) = $6.3B
June 19, 2015 - 2015 Impact Investor Conference
18:05 - "The most important thing about this asset is it as a wealth of human efficacy data that has been out there and the key opinion leading physicians love this technology. We're talking about 3 out former past presidents of the American Burn Association are going to be involved in this 10 patient phase 2 clinical study and we think there may be some means we can get an accelerated pathway from a market perspective."
20:00 - " Near term commercial opportunity . There is no competition in terms of technology that have both layers of own skin. This is the ownly technology out there. We think in the US it's a $500M market opportunity not to mention other things diabetic foot ulcers, burns that are less than 50%, 30%, as well as ultimately some kind of cosmetic opportunity..."
June 16, 2015 - BIO International Convention at 2:30 pm ET
15:00 - "We believe this program will significantly mitigate enterprise risk as well as expose us to tremendous upside because of the data that has been produced since the physician sponsored study that is publicly available ."
11/19/2014 - AMBS: ASTUTE DEAL BRINGS IN ANOTHER SHOT ON GOAL FOR AMARANTUS BIO
11/18/2014 - Amarantus Business Update Conference Call "And with ESS-W, we feel as though we have found just a tremendous opportunity."
4/10/2014 - Development of the Mechanical Properties of Engineered Skin Substitutes After Grafting to Full-Thickness Wounds
11/23/2010 - DoD awards Regenicin and Lonza $18 million to develop PermaDerm for severe burns
8/18/2010 - Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼